Medical/Pharmaceuticals
Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer
PLYMOUTH MEETING, Pennsylvania, June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being tested to tre...
2019-06-26 21:47
3353
Purecircle Holdings Announces Name Change to Pure CE
SINGAPORE, June 26, 2019 /PRNewswire/ -- Pure CE Pte Ltd, formerly Purecircle Holdings Pte Ltd today announced that it changed its corporate name from "Purecircle Holdings" to "Pure CE". Pure CE updated its corporate name and branding to better reflect its identity as a leading private equi...
2019-06-26 17:21
3001
Ossur Announces 2019-2020 Roster of Team Ossur Athletes
REYKJAVIK, Iceland, June 25, 2019 /PRNewswire/ -- Twenty-two accomplished para-athletes, including many of the world's most renowned and decorated Paralympians from across the globe, have been named to Team Össur, the global prosthetics and orthopaedics innovator announced today. Össur has been ...
2019-06-25 22:55
6975
Avalon University School of Medicine granted ACCM accreditation
YOUNGSTOWN, Ohio, June 25, 2019 /PRNewswire/ -- Avalon University School of Medicine (AUSOM) is excited and pleased to announce that they have been granted accreditation by the Accreditation Commission of Colleges of Medicine (ACCM). This is an significant milestone in the continuing growth and s...
2019-06-25 22:45
2084
I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States
GAITHERSBURG, Md., June 25, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces onJune 24, 2019, that the first patient has been dosed in a ...
2019-06-25 22:01
1911
Cedrus' Head of Life Sciences, Ms. Kimberly Nearing, invited to moderate a panel at 2019 SAPA Healthcare Investment Forum & Roadshow in New York City
HONG KONG, June 25, 2019 /PRNewswire/ -- Ms. Kimberly Nearing, Head of Life Sciences atCedrus Investments ("Cedrus"), was invited to moderate a panel at the 2019 SAPA Healthcare Investment Forum & Roadshow atColumbia University in New York City on 15th June 2019. The Sino-American Pharmaceutical...
2019-06-25 09:00
3285
Education Resources, Inc. Unveils New Website And Brand Identity
Improved Website and Updated Brand Logo Highlights Company's Continued Commitment to the Therapy Community BOSTON, June 25, 2019 /PRNewswire/ -- Education Resources, Inc. (ERI), a leading provider of continuing education courses for physical therapists, occupational therapists, and speech-langua...
2019-06-25 06:07
1856
Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies
SHANGHAI and NEW YORK, June 24, 2019 /PRNewswire/ -- Target Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capitalize on the rapid internationalization of clinical trials between the US andChina while maintain...
2019-06-25 04:00
2122
Medtech Nears its Golden Age Focusing on Value-based Care
Asia-Pacific to overtake Europe as the second largest market by 2022, finds Frost & Sullivan SANTA CLARA, California, June 25, 2019 /PRNewswire/ -- The key medtech industry challenges of lack of innovation in conventional segments, the evolution of GAFAM (Google, Amazon, Facebook, Apple, and Mic...
2019-06-25 01:12
2303
Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist
OSAKA, Japan, June 24, 2019 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi" or "the Company") announces that the Company has concluded an agreement with Eddingpharm (hereafter "Eddingpharm") to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name inJapan: MULPLETA® ...
2019-06-24 22:00
1881
Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres® Y-90 resin microspheres
Physicians and employees recognized for their role in this milestone and impact made on patient lives WOBURN, Massachusetts, June 24, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Sphe...
2019-06-24 21:00
2867
China Jo-Jo Drugstores Enters into Strategic Cooperation Framework Agreement with Zhejiang Medical Insurance Bureau
HANGZHOU, China, June 24, 2019 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a healthcare provider inChina, announced today that...
2019-06-24 20:30
7359
FDA Grants Orphan Drug Designation to XW Laboratories' XWL-008 for the Treatment of Patients with Narcolepsy
WUHAN, China, June 24, 2019 /PRNewswire/ -- XW Laboratories Inc. (XW Labs), a clinical-stage biopharmaceutical company pioneering the discovery of novel small molecule therapeutics for the treatment of neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has gr...
2019-06-24 17:00
3274
Mentice and Siemens Healthineers Bring a Virtual Patient to the Angio-suite
STOCKHOLM, June 24, 2019 /PRNewswire/ -- Siemens Healthineers, a leading medical technology company and Mentice AB, a world leader in simulation solutions for endovascular therapies, announced today the collaboration to fully integrate Mentice's VIST® Virtual Patient into the Artis icono angiogr...
2019-06-24 16:33
1858
Singapore Health Sciences Authority Approves Vosevi(R) (Sofosbuvir/ Velpatasvir/ Voxilaprevir) for Re-treatment of Adults with Chronic Hepatitis C Virus
SINGAPORE, June 24, 2019 /PRNewswire/ -- Gilead Sciences, Inc. today announced that the Singapore Health Sciences Authority has approved Vosevi (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), a once-daily single tablet regimen for the re-treatment of adults with genotype 1-6 chronic hepa...
2019-06-24 14:00
2333
Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist
OSAKA, Japan, June 24, 2019 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi" or "the Company") announces that the Company has concluded an agreement with Eddingpharm(hereafter "Eddingpharm") to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name inJapan: MULPLETA® )...
2019-06-24 10:00
1956
Acutus Medical Announces $170 Million Financing
CARLSBAD, California, June 24, 2019 /PRNewswire/ -- Acutus Medical today announced a$170 million financing, including a $100 million Series D equity financing and a$70 million credit facility. The funding is intended to accelerate commercialization and facilitate global business development acti...
2019-06-24 10:00
2142
Asieris Announces Completion of Enrollment for its US APL-1202 Phase Ib Clinical Trial
SHANGHAI, June 24, 2019 /PRNewswire/ -- Asieris, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, announced today the completion of enrollment for its APL-1202 Phase Ib trial in the US....
2019-06-24 09:00
2175
Concord Medical will hold online Q&A session on June 25th 2019
BEIJING, June 21, 2019 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solutions provider and an operator of the network of radiotherapy and diagnostic imaging centers inChina, today announced that...
2019-06-22 11:19
6536
European Medicines Agency Accepted First "China-Developed" Biosimilar - Henlius HLX02 Marketing Authorization Application for Review
* First China biosimilar conducted a multi-center, international phase 3 clinical trial * First trastuzumab developed in China following the National Medical Products Administration (NMPA) technical guideline for biosimilar with the New Drug Application (NDA) received the acceptance for revie...
2019-06-21 20:29
2637
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 318 media titles]
2024-05-07 08:00
VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation
[Picked up by 316 media titles]
2024-05-08 14:37
OPTIX raises US$15 million fundraising to date to solve the bottleneck of XR optics technology
[Picked up by 309 media titles]
2024-05-08 08:00IN2MF in Kuala Lumpur Presented by Bank Indonesia
[Picked up by 295 media titles]
2024-05-08 16:44
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
15085
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
10426
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
9812
